Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells 825 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 825 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total value of $24,354.00. Following the completion of the transaction, the insider now directly owns 83,664 shares of the company’s stock, valued at $2,469,761.28. The trade was a 0.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Nur Nicholson also recently made the following trade(s):

• On Wednesday, January 22nd, Nur Nicholson sold 3,948 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $30.43, for a total value of $120,137.64.
• On Friday, January 17th, Nur Nicholson sold 2,145 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total value of $64,264.20.

Apellis Pharmaceuticals Stock Up 3.3 %

Shares of NASDAQ APLS traded up $0.99 during midday trading on Thursday, hitting $30.46. 232,907 shares of the company’s stock were exchanged, compared to its average volume of 1,954,741. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $71.90. The company has a market cap of $3.79 billion, a PE ratio of -14.99 and a beta of 0.94. The firm’s fifty day simple moving average is $32.20 and its 200-day simple moving average is $32.96.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. During the same period last year, the business posted ($1.17) EPS. Apellis Pharmaceuticals’s revenue was up 78.3% on a year-over-year basis. Research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on APLS. Piper Sandler reduced their target price on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th. Morgan Stanley began coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They set an “equal weight” rating and a $31.00 target price for the company. Wells Fargo & Company reduced their target price on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. The Goldman Sachs Group downgraded Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 target price for the company. in a research note on Tuesday, December 17th. Finally, Mizuho dropped their price target on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research report on Thursday, October 24th. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $46.71.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in Apellis Pharmaceuticals by 23.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares during the last quarter. Braidwell LP grew its stake in shares of Apellis Pharmaceuticals by 410.8% in the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock valued at $90,130,000 after purchasing an additional 2,513,383 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of Apellis Pharmaceuticals by 51.6% in the 4th quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock valued at $88,084,000 after buying an additional 939,289 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Apellis Pharmaceuticals by 191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock valued at $61,845,000 after buying an additional 1,409,707 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Apellis Pharmaceuticals by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,810,526 shares of the company’s stock valued at $52,229,000 after buying an additional 22,609 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).